Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycopyrronium bromide crossover trial in children with asthma
2024-511382-11-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of glycopyrronium in asthma, sponsored by Novartis. Primary endpoint: Change from baseline in trough FEV1 at week 2. Planned start Jun 2024; status: authorised.
02
Drugs
glycopyrronium
03
Conditions
asthma
Beyond the preview
Go deeper on 2024-511382-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511382-11-00.